Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04841226 · ClinicalTrials.gov registry record · NA
Randomized Study of Silq Urinary Catheter
A NA study, sponsored by Silq Technologies Corporation.
- Completed
- Registry status
- NA
- Development phase
- 158
- Enrollment target
NCT04841226: Completed NA study, sponsored by Silq Technologies Corporation.
NCT04841226 is a NA study that has completed, run by Silq Technologies Corporation. The registered enrollment target is 158 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04841226, a NA study, has completed, sponsored by Silq Technologies Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 158 participants
- Enrollment target
Study Summary
To assess the ability of the Silq ClearTract™ 100% Silicone 2-Way Foley Catheter to reduce biofilm formation in subjects that require a long-term indwelling Foley catheter when compared to other commercially available urinary catheters.
Primary Outcome
A core lab will use the BacTiter-Glo Microbial Cell Viability Assay, a well characterized method for quantifying active biomass and biofilm, to determine biofilm formation on explanted catheter samples.
Interventions
- DEVICE Long-term indwelling Foley catheter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2021-12-28 |
| Est. Completion | 2024-08-15 |
| Phase | NA |
What the finished NCT04841226 record still lists
NCT04841226 is an interventional study that assigns participants to a tested intervention. The registered 158 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which Long-term indwelling Foley catheter is the first listed.
NCT04841226 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04841226 about?
NCT04841226 is a clinical study titled "Randomized Study of Silq Urinary Catheter". To assess the ability of the Silq ClearTract™ 100% Silicone 2-Way Foley Catheter to reduce biofilm formation in subjects that require a long-term indwelling Foley catheter when compared to other commercially available urinary catheters.
What is the current status of trial NCT04841226?
This trial is currently completed. It is a NA study. The enrollment target is 158 participants. The study started on 2021-12-28. Estimated completion is 2024-08-15.
What interventions are being tested in trial NCT04841226?
The interventions under investigation include: Long-term indwelling Foley catheter (DEVICE).
Who is sponsoring clinical trial NCT04841226?
This trial is sponsored by Silq Technologies Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04841226's enrollment target sits among peer trials
158 654th of 2000 higher than 1,345 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04486833 · 158 participants · Phase 1
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
- NCT04697966 · 158 participants · NA
Mechanisms and Predictors of Change in App-Based Mindfulness Training for Adolescents
- NCT04969835 · 158 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
- NCT05230732 · 158 participants · NA
Neuromodulation of Inflammation and Endothelial Function
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI